Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | GINECO TAPAZ clinical trial update

Florence Joly, MD, PhD, Centre François Baclesse, Caen, France, discusses the GINECO randomized Phase II TAPAZ (NCT02383251) study, comparing the use of paclitaxel with or without pazopanib in ovarian cancer patients with relapse during bevacizumab maintenance therapy. Primary endpoint was progression-free survival (PFS), results did not show an increase in PFS in favour of the combination treatment, with Prof. Joly concluding that the combination treatment is not really feasible. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).